+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effect on LDL cholesterol LDL-C and the safety and tolerability of a fixed-dose combination FDC of Laroprovstat and Rosuvastatin in patients who have not previously received lipid-lowering treatment LLT. Laroprovstat is a small molecule developed to reduce LDL-C in the blood, and this Phase III randomized study compares this combination with Laroprovstat alone, Rosuvastatin alone, and placebo in people with hypercholesterolaemia. Participants will be randomly assigned to one of several groups receiving daily oral doses of Laroprovstat, Rosuvastatin at two dose levels, the combination LaroprovstatRosuvastatin at two dose levels, or placebo matching these treatments. The study uses a factorial design and is double-blind, meaning neither participants nor researchers know which treatment is given. Treatment lasts for 8 weeks with assessments focused on changes in LDL-C levels. During the study, participants will attend visits for evaluations including blood tests to measure LDL-C and other cholesterol-related markers such as Apo B, non-HDL cholesterol, and total cholesterol. The main outcome measured is the relative change in LDL-C at 8 weeks. Safety and tolerability will also be monitored throughout. The entire participation period covers the treatment and assessment over the 8-week period.

Age: 18Years - 130YearsAll GendersPhase 3
152 locations
E

Actively Recruiting

Researchers are evaluating the combined use of finerenone and empagliflozin compared to usual care to assess their safety and effectiveness in patients hospitalized with heart failure. This international, randomized, controlled, open-label trial aims to study an early, intensive management approach for heart failure treatment. Participants will be assigned to receive either the combination of oral finerenone plus oral empagliflozin or usual care. The study focuses on treatment during hospitalization and shortly after, comparing these approaches to understand the clinical benefits and risks over a six-month period. During the trial, participants will be monitored for clinical outcomes including serious adverse events and events leading to treatment discontinuation. Researchers will measure heart failure events, symptom changes using the Kansas City Cardiomyopathy Questionnaire, and overall survival up to six months. Safety and efficacy data will be collected throughout the study period ending in November 2027.

Age: 18Years +All GendersPhase 3
140 locations
E

Actively Recruiting

Researchers are evaluating the combination of baxdrostat and dapagliflozin compared with dapagliflozin alone in adults aged 40 years and older who have type 2 diabetes, established cardiovascular disease, a history of hypertension with elevated systolic blood pressure, and at least one additional risk factor for heart failure. This phase III trial aims to assess whether adding baxdrostat can reduce the risk of heart failure events or cardiovascular death. Participants will be randomly assigned to receive either baxdrostat with dapagliflozin or placebo with dapagliflozin. Those not currently on SGLT2 inhibitors or treated for less than 4 weeks will enter a run-in period taking dapagliflozin alone for 4 to 6 weeks before randomization. Doses of baxdrostat may be increased if criteria are met. Study visits occur at 2, 4, 8, 16, and 34 weeks after randomization and then approximately every 4 months until the study ends when enough cardiovascular events have occurred. During the study, participants will have regular assessments including blood pressure and laboratory tests to monitor safety and efficacy. If participants stop the blinded study treatment early, they may continue open-label dapagliflozin. The main outcome is to see if the combination reduces heart failure events or cardiovascular death compared to dapagliflozin alone, with follow-up lasting up to 38 months. Data collection and scheduled visits will continue throughout the study period.

Age: 40Years +All GendersPhase 3
977 locations
R

Actively Recruiting

Researchers are evaluating how rifaximin 200 mg is processed in the bodies of children aged 6 to 11 years who have acute diarrhea possibly caused by bacteria. The study also aims to assess the safety and effectiveness of rifaximin combined with oral rehydration therapy ORT compared to ORT alone in this pediatric group. This is a phase 4, randomized, open-label trial focusing on treatment outcomes and pharmacokinetics. Participants will be randomly assigned to receive either rifaximin 200 mg tablets three times daily for 3 days combined with ORT or ORT alone according to standard care. The rifaximin group will have blood samples collected on Day 1 and Day 3 to measure drug levels at specific times. All participants will receive ORT as per investigators standard of care and will keep a diary tracking stool frequency, consistency, and symptoms. Participants will attend up to 4 clinic visits during a 5-day treatment period, including screening, Day 1, Day 3 end of treatment, and Day 5 last clinic visit. They will also receive two follow-up phone calls for safety monitoring up to Day 30. Assessments include stool samples to identify bacterial pathogens, blood tests for pharmacokinetics, monitoring for side effects, vital signs, and laboratory tests. The main outcomes measured include rifaximin plasma levels and the proportion of participants achieving clinical cure by Day 5.

Age: 6Years - 12YearsAll GendersPhase 4
10 locations
R

Actively Recruiting

Researchers are evaluating the safety and effectiveness of VE303, a live biotherapeutic product, in preventing the recurrence of Clostridioides difficile infection CDI. This study focuses on participants with either recurrent CDI or primary CDI at high risk for recurrence, assessing the recurrence rate at 8 weeks after treatment. The study is a randomized, double-blind, placebo-controlled Phase 3 trial sponsored by Vedanta Biosciences, Inc. Participants receive either VE303 or a matching placebo after completing 10 to 21 days of standard antibiotic treatment for their CDI episode. Those assigned to the VE303 group take 3 capsules daily for 14 days the placebo group takes 3 placebo capsules daily for the same duration. The capsules look identical to ensure blinding. This treatment period follows the completion of their initial antibiotic therapy. Throughout the study, participants are monitored for CDI recurrence up to 8 weeks after treatment. Researchers evaluate safety and measure the rate of CDI coming back during this period. Participants must have completed standard antibiotic therapy and meet clinical stability criteria before starting the study drug. The total participation time includes screening, treatment, and observation phases until the primary outcome at week 8 is assessed.

Age: 12Years +All GendersPhase 3
215 locations